GHGuardant Health, Inc.

Nasdaq guardanthealth.com


$ 27.24 $ 0.89 (3.36 %)    

Thursday, 30-May-2024 13:40:37 EDT
QQQ $ 454.82 $ -1.60 (-0.35 %)
DIA $ 398.57 $ 0.65 (0.17 %)
SPY $ 530.36 $ 0.68 (0.13 %)
TLT $ 91.26 $ 0.29 (0.33 %)
GLD $ 225.37 $ 0.21 (0.1 %)
$ 26.09
$ 26.35
$ 27.09 x 106
$ 27.27 x 100
$ 26.07 - $ 27.50
$ 15.81 - $ 41.06
2,064,970
na
3.18B
$ 1.19
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 02-22-2024 12-31-2023 10-K
3 11-06-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 02-23-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 03-02-2020 12-31-2019 10-K
19 11-07-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-10-2019 03-31-2019 10-Q
22 03-19-2019 12-31-2018 10-K
23 11-19-2018 09-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cathie-wood-led-ark-invest-cuts-robinhood-holdings-amid-bitcoin-dip-keeps-selling-moderna-stock--buys-palantir-and-amd-shares

On Wednesday, Ark Invest, led by the influential investor Cathie Wood, executed notable trades involving Robinhood Markets Inc ...

 stephens--co-reiterates-overweight-on-guardant-health-maintains-44-price-target

Stephens & Co. analyst Mason Carrico reiterates Guardant Health (NASDAQ:GH) with a Overweight and maintains $44 price ta...

 fda-advisory-panel-supports-approval-of-guardant-healths-blood-test-for-colorectal-cancer-screening

FDA panel recommends approval for Guardant Health's Shield blood test for colorectal cancer screening.

Core News & Articles
Market-Moving News for May 24th
05/24/2024 12:46:45

MRUS: 23% | Merus shares are trading higher after the company announced the publication of an abstract regarding petosemtamab i...

 reported-earlier-guardant-healths-shield-blood-test-for-colorectal-cancer-screening-receives-strong-recommendation-from-fda-advisory-committee-paving-the-way-for-approval

The advisory committee offers valuable non-binding recommendations for the FDA Blood test offers a convenient non-invasive s...

 guardant-health-says-stock-trading-temporarily-halted-as-fda-panel-to-assess-premarket-approval-application-for-shield-blood-test-for-colorectal-cancer-screening

The Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee wil...

 whats-going-on-with-colorectal-cancer-diagnostic-focused-guardant-health-stock-on-tuesday

FDA staff reviewers raise concerns over Guardant Health's experimental Shield blood test for colorectal cancer, citing low ...

 fda-staff-in-briefing-documents-says-guardant-healths-test-may-fail-to-detect-some-types-of-advanced-adenomas-in-patients

-Reuters Citing Docs

 guardant-healths-real-world-data-supporting-performance-of-shield-blood-test-for-crc-presented-at-2024-digestive-disease-week

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will present data from two real-wor...

 correction-guardant-health-q1-2024-adj-eps-046-beats-085-estimate-sales-168500m-beat-150673m-estimate

Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.85)...

 canaccord-genuity-maintains-buy-on-guardant-health-lowers-price-target-to-30

Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:GH) with a Buy and lowers the price target from $45 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION